See the Results

What KESIMPTA® can do


Results that speak for themselves

KESIMPTA was effective in reducing the relapsing MS activity you see (relapses and disability progression), and the activity you don’t (lesions).
KESIMPTA went head-to-head with AUBAGIO® in 2 studies. Over 1,800 people aged 18-55 years with relapsing MS participated. All of them had a relapse or saw activity on an MRI in the last 1–2 years leading up to the studies. Each person received KESIMPTA or AUBAGIO for up to 30 months.
gray text callout
Not only are relapses unpredictable, but they interrupt your day-to-day.
Imagine fewer relapses.
gray text callout
Knowing disability could get worse can be top of mind for people with relapsing MS.
What if there were less chance of your disability progressing?
*This was based on whether or not disability progression was still present 3 and 6 months after disability symptoms started.
gray text callout
If these lesions show up, it may mean your relapsing MS is more active than you’re aware of.
How would you feel walking into an MRI if you knew there could be less of these lesions?
gray text callout
These lesions, both old and new, show the impact relapsing MS has on the brain.
What if you could expect significantly less of these lesions?
Text callout
You’ve seen what KESIMPTA can do
Start the convo with your doctor to see if it’s right for you
Gd+=gadolinium-enhancing; MS=multiple sclerosis.
AUBAGIO (teriflunomide), an oral relapsing MS treatment, is a registered trademark of Sanofi and Genzyme.